Observational studyClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Vitamin K Antagonist Treatment Burden Assessed with the Patient Reported Outcome "Anti Clot Treatment Scale": KAFe Trial, a Single-Center Study Involving 202 Patients.
Observational study in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vitamin K antagonists (VKAs) remain essential in selected patients requiring anticoagulation. Patient satisfaction, essential for adherence and outcomes, can be evaluated using the Anti-Clot Treatment Scale (ACTS).In the prospective, single-center KAFe trial, 202 patients on VKA therapy attending the Ferrara Hematology Center were enrolled in January-March 2025. Clinical and demographic data were collected, and ACTS was administered during routine INR monitoring.Highly satisfied patients were more frequently male, older, and had an ECOG performance status ≥1. In multivariate analysis, male sex (OR 1.8) and ECOG ≥1 (OR 2.1) independently predicted higher satisfaction.ACTS benefit scores were consistently high across the cohort, whereas burden scores varied according to age, sex, ECOG status, history of venous thrombosis, and duration of VKA therapy.Incorporating ACTS into routine practice may support patient-centered counseling and shared anticoagulation decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.